Business

Title Due Date Maximum Award Amount Sort descending Description
Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional) Varies

Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional)

https://www.grants.gov/web/grants/view-opportunity.html?oppId=347228
New Markets Tax Credit Program No Due Date Given Varies

Created by the U.S. Federal Government in 2000 as part of the Community Renewal Tax Relief Act, the New Markets Tax Credit (NMTC) program encourages investment in low-income communities. Through the NMTC Program, real estate projects or businesses in a low-income community are able to generate capital by providing investors- typically a bank or financial institution- a tax credit as an additional incentive for capital investment.

New Markets Tax Credit Program
Truckee Donner PUD Rebate Programs No Due Date Given Varies

Truckee Donner PUD offers a variety of residential and business programs and services to help our customers save money while conserving resources.  Click below to learn more information about our programs and how they can help your home or business.

https://www.tdpud.org/customer-service/conservation
Glenn County APCD Carl Moyer Program No Due Date Given Varies

The program achieves near-term reductions in emissions of oxides of nitrogen (NOx), particulate matter (PM), and reactive organic gas (ROG) which are necessary for California to meet its clean air commitments under the State Implementation Plan. NOx and ROG combine in the presence of sunlight to form ozone (smog), while PM, a component of diesel exhaust, has been identified as a toxic air contaminant by the Air Resources Board. Please contact our office with any questions that you may have at (530) 934-6500 or visit the California Air Resources Board Carl Moyer Program web site. The application period typically runs from December until early March of each year.

https://www.countyofglenn.net/dept/agriculture/air-pollution-control-district/grant-programs/carl-moyer-program
North Coast Unified AQMD Carl Moyer Program No Due Date Given Varies

The Carl Moyer Memorial Air Quality Standards Attainment Program (Carl Moyer Program) provides incentive grants for cleaner-than-required engines, equipment, and other sources of pollution providing early or extra emission reductions. Eligible projects include cleaner on-road, marine, and agricultural sources. Projects may include engine re-powers, the purchase of new vehicles using alternative fuels, and engine retrofit devices approved by the California Air Resources Board (CARB). The District implements the program from funding received from CARB.

http://www.ncuaqmd.org/index.php?page=carl.moyer
ALTERNATIVE TO OPEN Ag BURNING INCENTIVE PILOT PROGRAM No Due Date Given Varies

The Alternative to Agricultural Open Burning Incentive Pilot Program provides incentives to commercial agricultural operations located within Valley Air District boundaries to chip or shred agricultural material. The material must be used for soil incorporation or land application on agricultural land as an alternative to the open burning of the agricultural materials. Complete applications are processed on a first-come, first-served basis while funds are available.

https://valleyair.org/grants/alt-ag-burning.htm
GoGreen Financing No Due Date Given Varies

Whether you want to reduce energy usage, improve the comfort and health of your home or business, or just want to “go green,” you can find the solution you need. GoGreen Financing serves three broad property types:

  • Residential
  • Affordable Multifamily
  • Business

The California Public Utilities Commission authorized the California investor-owned utilities (PG&E®, SDG&E®, SCE® and SoCalGas®) to collaborate with certain state agencies in the development of energy efficiency financing programs and to assist in building awareness about them. Consumers are encouraged to explore lending options for the financing of energy improvements that can make homes and businesses more efficient and comfortable.

HEAL Initiative: Rapidly Assessing the Public Health Impact of Emerging Opioid Threats (UG1 - Clinical Trial Optional) Varies

The need to rapidly develop methods to assess the prevalence / health impact of emerging illicit drugs has never been greater. Illicit chemists are marketing potent drugs of abuse taken from deep wells of scientific and patent literature, which we can expect to continue to yield new drugs for many years. Over the last few years, fentanyl/fentalogs (fentanyl-related opioids) have flooded the illicit opioid market, which has complicated patient stabilization / harm reduction, and caused mortality rates to skyrocket. Even understanding the drugs being used is difficult due to unstandardized analytical methods, and urine test strip kit variabilities. When test strips do detect fentalogs they simply indicate fentanyl and clinicians base treatment on this homogenous grouping. However, it is unclear that the addictive or mortality risk of fentalogs are generalizable. Initially fentanyl was reported to be long-lasting and poorly antagonizable, but such reports diminished when carfentanil, an ultrapotent and long-lasting fentalog, diminished in drug supplies. Now, ultrapotent "nitazene" opioids are on the market and a lack of validated analytical protocols and standards, has meant these drugs are over-looked in most jurisdictions. Nitazene urine test strips do not yet exist and so clinicians are ill-equipped to recognize nitazenes and respond appropriately. Users certainly do not know whether nitazenes (or fentalogs) are illicit purchased drugs. This FOA promotes development and distribution of tools to detect nitazenes in the necessary range of settings needed to enable appropriately calculated responses. Additionally, this RFA builds-in funds to allow awardees to rapidly bring their discoveries and expertise to bear on the future generations of threats that are surely coming

https://www.grants.gov/web/grants/view-opportunity.html?oppId=341849
Cellular and Molecular Mechanisms of Prion-Like Aggregate Seeding, Propagation, and Neurotoxicity in AD/ADRD (R01 Clinical Trial Not Allowed) Varies

The accumulation of misfolded proteins in the brain is a key pathological feature shared by many neurodegenerative diseases that can result in dementia such as Alzheimers Disease, Lewy Body Diseases, Frontotemporal Degeneration, and cerebral amyloid angiopathy. Classical prion diseases such as Creutzfeldt-Jakob Disease are a rare family of neurodegenerative disorders that occur when the cellular prion protein (PrPC) undergoes structural conversion to a pathological form (PrPSc), which is usually triggered by its interaction with an infectious variant of the protein that forces the conformational change. Once this process is initiated, it becomes self-propagating until toxic aggregates accumulate within the CNS, leading to neuronal death. Because misfolded proteins of AD/ADRD have been reported to share some features with pathological prion protein at the structural level, it has thus been proposed that ADRD-relevant proteins such as Alpha, tau, beta-synuclein, and TDP-43 (among others) may exhibit prion-like behaviors that lead to toxic aggregate and tangle formation. The goal of this initiative is to promote studies that increase our understanding of the cellular and molecular mechanisms by which such prion-like conversion events occur and are propagated in AD/ADRD, as well as the downstream mechanisms that trigger neurotoxicity, pathological and circuit changes in the brain.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=342734
HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed) Varies

The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=343551